Investigators reported 1-year disease-free survival results from patients with BCG-unresponsive papillary disease-only high-risk NMIBC in the phase 2b SunRISe-1 trial.

An existing oral drug already used to treat lung cancer could help improve survival rates for bladder cancer patients, a new clinical trial by UK scientists has found. There are approximately 10,300 ...

A phase 2 study of Johnson & Johnson's Inlexzo (gemcitabine intravesical system) found strong survival results after one year ...

TAR-200 demonstrated high DFS and bladder preservation rates in BCG-unresponsive, high-risk non-muscle-invasive bladder cancer with papillary-only disease. The phase 2b SunRISe-1 study showed over 80% ...

LAS VEGAS -- Patients with high-risk, treatment-unresponsive non-muscle invasive bladder cancer (NMIBC) had an unprecedented response rate and disease-free survival (DFS) with an investigational ...

Sequential therapy yields lower survival and response rates in upper tract urothelial carcinoma versus bladder cancer. Learn ...

PADCEV plus KEYTRUDA is the first and only regimen to improve survival when used before and after standard of care (surgical cystectomy) in cisplatin-ineligible patients with muscle-invasive bladder ...

Non-muscle invasive bladder cancer is cancer that’s only in the inner lining of your bladder. It hasn’t grown into the muscle wall. Your doctor may also call it superficial bladder cancer, urothelial ...

In November 2025, the U.S. Food and Drug Administration (FDA) issued several approvals across oncology and supportive care.